Jeffrey W. Albers - 03 Mar 2022 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Ariel Hurley, Attorney-in-Fact
Issuer symbol
BPMC
Transactions as of
03 Mar 2022
Net transactions value
-$1,692,062
Form type
4
Filing time
08 Mar 2022, 15:06:06 UTC
Previous filing
03 Mar 2022
Next filing
08 Apr 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Sale $473,921 -7,862 -4% $60.28 188,086 03 Mar 2022 Direct F1
transaction BPMC Common Stock Options Exercise $14,025 +7,500 +4% $1.87* 195,586 04 Mar 2022 Direct F2
transaction BPMC Common Stock Options Exercise $187,625 +12,500 +6.4% $15.01 208,086 04 Mar 2022 Direct F2
transaction BPMC Common Stock Sale $569,214 -10,055 -4.8% $56.61 198,031 04 Mar 2022 Direct F2, F3
transaction BPMC Common Stock Sale $256,299 -4,445 -2.2% $57.66 193,586 04 Mar 2022 Direct F2, F4
transaction BPMC Common Stock Sale $238,948 -4,100 -2.1% $58.28 189,486 04 Mar 2022 Direct F2, F5
transaction BPMC Common Stock Sale $83,202 -1,400 -0.74% $59.43 188,086 04 Mar 2022 Direct F2, F6
transaction BPMC Common Stock Sale $272,128 -4,843 -2.6% $56.19 183,243 07 Mar 2022 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -7,500 -5.5% $0.000000 127,903 04 Mar 2022 Common Stock 7,500 $1.87 Direct F2, F8
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -12,500 -16% $0.000000 65,000 04 Mar 2022 Common Stock 12,500 $15.01 Direct F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $56.03 to $57.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $57.04 to $58.01 per share.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $58.05 to $58.63 per share.
F6 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $59.10 to $59.89 per share.
F7 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $56.18 to $56.90 per share.
F8 This option was granted on July 30, 2014 and is fully vested as of the date hereof.
F9 This option was granted on February 3, 2016 and is fully vested as of the date hereof.